Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Ovid Therapeutics

07/08/2023 14:02

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly
adjusted
loss of 18 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 20 cents per share.
    * Revenue was $75.00 thousand​; analysts expected $47.75
thousand. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was a
loss
of 18 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ovid Therapeutics Inc shares had risen by 6.7% this
quarter and
gained 88.2% so far this year.
    * The company reported a quarterly loss of $12.41 million.
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 01:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.20          -0.18          Beat
 Mar. 31 2023      -0.17          -0.19          Missed
 Dec. 31 2022      -0.18          -0.16          Beat
 Sep. 30 2022      -0.21          -0.17          Beat